TY - JOUR
T1 - Effect of antidepressant treatment on plasma levels of neuroinflammation-associated molecules in patients with somatic symptom disorder with predominant pain around the orofacial region
AU - Miyauchi, Tomoya
AU - Tokura, Tatsuya
AU - Kimura, Hiroyuki
AU - Ito, Mikiko
AU - Umemura, Eri
AU - Sato (Boku), Aiji
AU - Nagashima, Wataru
AU - Tonoike, Takashi
AU - Yamamoto, Yasuko
AU - Saito, Kuniaki
AU - Kurita, Kenichi
AU - Ozaki, Norio
PY - 2019/7
Y1 - 2019/7
N2 - Objective: Burning mouth syndrome (BMS) and atypical odontalgia (AO) are examples of somatic symptom disorders with predominant pain around the orofacial region. Neuroinflammation is thought to play a role in the mechanisms, but few studies have been conducted. We aimed to better understand the role of neuroinflammation in the pathophysiology and treatment of BMS/AO. Methods: Plasma levels of 28 neuroinflammation-related molecules were determined in 44 controls and 48 BMS/AO patients both pretreatment and 12-week post-treatment with duloxetine. Results: Baseline plasma levels of interleukin (IL)-1β (p <.0001), IL-1 receptor antagonist (p <.001), IL-6 (p <.0001), macrophage inflammatory protein-1β (p <.0001), and platelet-derived growth factor-bb (.04) were significantly higher in patients than in controls. Plasma levels of granulocyte macrophage colony stimulating factor were significantly higher in patients than in controls (p <.001) and decreased with treatment (.009). Plasma levels of eotaxin, monocyte chemoattractant protein-1, and vascular endothelial growth factor decreased significantly with treatment (p <.001,.022, and.029, respectively). Conclusions: Inflammatory mechanisms may be involved in the pathophysiology and/or treatment response of somatic symptom disorders with predominant pain around the orofacial region.
AB - Objective: Burning mouth syndrome (BMS) and atypical odontalgia (AO) are examples of somatic symptom disorders with predominant pain around the orofacial region. Neuroinflammation is thought to play a role in the mechanisms, but few studies have been conducted. We aimed to better understand the role of neuroinflammation in the pathophysiology and treatment of BMS/AO. Methods: Plasma levels of 28 neuroinflammation-related molecules were determined in 44 controls and 48 BMS/AO patients both pretreatment and 12-week post-treatment with duloxetine. Results: Baseline plasma levels of interleukin (IL)-1β (p <.0001), IL-1 receptor antagonist (p <.001), IL-6 (p <.0001), macrophage inflammatory protein-1β (p <.0001), and platelet-derived growth factor-bb (.04) were significantly higher in patients than in controls. Plasma levels of granulocyte macrophage colony stimulating factor were significantly higher in patients than in controls (p <.001) and decreased with treatment (.009). Plasma levels of eotaxin, monocyte chemoattractant protein-1, and vascular endothelial growth factor decreased significantly with treatment (p <.001,.022, and.029, respectively). Conclusions: Inflammatory mechanisms may be involved in the pathophysiology and/or treatment response of somatic symptom disorders with predominant pain around the orofacial region.
UR - http://www.scopus.com/inward/record.url?scp=85066912556&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066912556&partnerID=8YFLogxK
U2 - 10.1002/hup.2698
DO - 10.1002/hup.2698
M3 - Article
C2 - 31125145
AN - SCOPUS:85066912556
VL - 34
JO - Human Psychopharmacology
JF - Human Psychopharmacology
SN - 0885-6222
IS - 4
M1 - e2698
ER -